Situs Slot Gacor https://new.c.mi.com/ph/post/145937/12_Situs_Judi_Slot_Terbaik_dan_Terpercaya_No_1__Da https://new.c.mi.com/ph/post/148085/Daftar_10_Situs_Judi_Slot_Terbaik_Dan_Terpercaya_N https://new.c.mi.com/ph/post/148080/Daftar_10_Situs_Judi_Slot_Terbaik_Dan_Terpercaya_N https://new.c.mi.com/ph/post/148006/Daftar_Bocoran_Slot_Gacor_Hari_Ini_2022_Terbaru__J https://new.c.mi.com/ph/post/146162/Slot_Gacor__Pola_Jam_Hoki_Main_Slot_Gacor_Gates_of https://new.c.mi.com/ph/post/148300/Link_Daftar_19_Situs_Slot_Gacor_Mudah_Menang_Jackp https://new.c.mi.com/ph/post/146128/Daftar_10_Situs_Slot_Gacor_Hari_Ini_Terbaru_Terper https://new.c.mi.com/ph/post/148211/Situs_Slot_Hoki_Gacor_Hari_Ini_Dan_Pola_Jam_Main_G Slot Gacor Gampang Menang Situs Slot Gacor https://gms.dpe.go.th/mobile/public/admin/ckfinder/plugins/fileeditor/situs-judi-slot-terbaik-dan-terpercaya-no-1/ http://portalsewa.mais.gov.my/img/icons/largest/slot-online-gacor-terbaru/ https://new.c.mi.com/ph/post/161002/AGEN_SLOT_DEMO_GRATIS__SLOT_DEMO_PG_SOFT__SLOT_DEM https://new.c.mi.com/ph/post/160997/KUMPULAN_SLOT_GACOR__DAFTAR_10_SITUS_SLOT_GACOR_20 https://new.c.mi.com/ph/post/163500/17_SLOT_GACOR_88_SLot_Situs_Judi_Slot_Online_Terpe https://new.c.mi.com/ph/post/161273/LINK_SLOT_GACOR_4D__SITUS_SLOT_ONLINE_GACOR_GAMPAN https://new.c.mi.com/ph/post/161268/Daftar_Link_Slot_4D__Daftar_Situs_Slot_Gacor_4D_Re https://new.c.mi.com/ph/post/162611/Link_Daftar_Situs_Slot_Gacor_Resmi_Terpercaya_2022 https://new.c.mi.com/ph/post/161263/Daftar_Persatuan_Situs_Slot_Bonus_100_New_Member_T https://new.c.mi.com/ph/post/162079/DAFTAR_REKOMENDASI_SITUS_JUDI_SLOT_GACOR_TERPERCAY https://new.c.mi.com/ph/post/162074/17_Daftar_Link_Situs_Slot_Gacor_Terpercaya_2022_Ga https://new.c.mi.com/ph/post/162616 https://new.c.mi.com/ph/post/166560/DAFTAR_17_NAMA_SITUS_JUDI_SLOT_GACOR_GAMPANG_MENAN https://new.c.mi.com/ph/post/166555/Situs_Slot_Pulsa__Situs_Slot_Deposit_5000_Via_Puls https://new.c.mi.com/ph/post/164278/Daftar_Situs_Judi_Slot_Online_Deposit_Pulsa_5000_T https://new.c.mi.com/ph/post/163807/21_Daftar_Situs_Judi_Slot_Gacor_Hari_Ini_Link_Judi https://new.c.mi.com/ph/post/165371/11_NAMA_SITUS_DAFTAR_JUDI_SLOT_GACOR_GAMPANG_MENAN https://new.c.mi.com/ph/post/165014/INFO_BOCORAN_SLOT_GACOR_PRAGMATIC_PLAY_RTP_LIVE_TE https://new.c.mi.com/ph/post/166535/Situs_Judi_Slot_Gacor_Malam_Ini_Cepat_Maxwin_Gampa https://new.c.mi.com/ph/post/163787/19_Kumpulan_Link_Daftar_Situs_Slot_Gacor_Terbaru_G https://new.c.mi.com/ph/post/165004/Daftar_Situs_Slot_Gacor_Bet_Kecil_100_200_Terperca https://new.c.mi.com/ph/post/164273/KUMPULAN_19_LINK_SITUS_SLOT_JUDI_GACOR_TERBARU_202
Business

Moderna says new booster increases protection against omicron subvariants




Comment

Vaccine maker Moderna announced Monday that its new omicron-targeted booster shot boosts a key line of immune defense by boosting levels of coronavirus-fighting antibodies that block BA.5. This omicron subvariant predominated in the United States until recently and still accounts for nearly a third of reported cases.

In blood taken from people who received the bivalent booster, levels of omicron-blocking antibodies increased 15 times higher than pre-booster levels, Moderna said in a news release. The findings, which have not yet been peer-reviewed, are similar to results that Pfizer and its German partner, BioNTech, presented this month about their bivalent coronavirus vaccine booster.

The data are encouraging because they show that the bivalent booster shots, which were updated to match the BA.4 and BA.5 versions of the omicron variant and began rolling out in September, offer protection against newer coronavirus variants ahead of a possible winter wave of cases.

Moderna also said that a preliminary analysis with a small number of subjects showed that the antibodies generated by the bivalent booster lost some potency against the challenging and fast-growing BQ.1.1 subvariant – but could still block it. BQ.1.1 accounts for about a quarter of cases in the United States, according to the Centers for Disease Control and Prevention.

“Evolution is a dangerous thing to bet against. The virus continues to surprise us, and we must be ready to update the vaccine, says Stephen Hoge, Moderna’s president. But he added that he was encouraged by the high antibody levels induced by the booster shot as the country heads into winter.

“I think we’re optimistic that this BA.4/BA.5-containing bivalent is going to be sufficient to get us through,” Hoge said.

Moderna’s announcement will fascinate researchers thinking about future booster strategies because the makers of both messenger RNA coronavirus vaccines have now presented converging results showing that their bivalent shots trigger a stronger response than their original formulations.

But the news is a bit of an artificial comparison to the general public because the original boosters are no longer available. The decision to switch was made over the summer to ensure enough supply to vaccinate people with the updated shots ahead of a potential winter wave of cases.

It is also unclear whether the data will help ignite public interest in the boosters. Only about 10 percent of people 5 and older in the United States has received a bivalent booster, according to CDC data.

To measure the effect of the extra shot, researchers compared the virus-blocking antibodies in the blood of 511 people, before and after the bivalent booster or the original. What these types of laboratory experiments cannot predict is how well or how long the higher antibody levels will protect people from infection or serious illness. Most researchers expect that the boosters will help strengthen protection against the worst outcomes, but will not provide as robust protection against infections.

Moderna reported that its bivalent booster created five to six times the level of antibodies compared to the older booster. It is a stronger advantage than the effect of a previous bivalent booster tuned to combat the BA.1 variant. But some researchers have questioned whether differences between the two groups of people who received each type of shot may be partially responsible for some of the benefits.

In contrast, Novavax, a latecomer to the vaccine race, presented data last week suggesting that a bivalent booster of the shot that included the omicron BA.1 subvariant did not provide an advantage over the original booster.

The company did not present data on a BA.4/BA.5-containing bivalent vaccine, but argued that its original shot could continue to offer protection, rather than updating the formula. It is unclear why there are divergent results. Novavax’s chief medical officer, Filip Dubovsky, said last week that the company’s shot can induce a broader response to the variants, which is then boosted by repeated boosts of the older formulation. Unlike the widely used messenger RNA vaccines from Pfizer-BioNTech and Moderna, the Novavax shot is a protein-based vaccine with an added substance called an adjuvant designed to rewire the immune system.

Novavax has said it may update the image if required by regulatory agencies.

“We’re kind of ready to respond to what’s required,” Dubovsky said. “But we actually think we have a case that sticking with what we have now, and seems to be working now, is the way to go into the future.”



Source link

Back to top button